Entries |
Document | Title | Date |
20080207633 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity. | 08-28-2008 |
20080214561 | SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE - The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions. The compounds of present invention are suitable for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease. | 09-04-2008 |
20080221117 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity. | 09-11-2008 |
20080255142 | Substituted Piperidine Derivatives as Somatostatin Sst1 Receptor Antagonists - Compound of the formula (I) wherein R | 10-16-2008 |
20080261993 | Insecticidal 3-(Dihaloalkenyl) Phenyl Derivatives -
Certain novel 3-(dihaloalkenyl)phenyl derivatives have unexpected insecticidal activity. These compounds are represented by formula (I), where R through R | 10-23-2008 |
20080261994 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF - The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): | 10-23-2008 |
20080306084 | Substituted Amide Compounds - Substituted amide compounds corresponding to formula I: | 12-11-2008 |
20080306085 | NON-IMIDAZOLE ARYLOXYALKYLAMINES - Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions. | 12-11-2008 |
20090042901 | AGENT FOR PREVENTION/THERAPY OF DISEASE CAUSED BY KERATINOCYTE GROWTH - The present invention relates to an agent for the prevention/therapy of a disease caused by keratinocyte growth, which comprises, as an active ingredient, a compound represented by General Formula (1): | 02-12-2009 |
20090042902 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 02-12-2009 |
20090042903 | PIPERAZINYL-PYRIDINE DERIVATIVES - The present invention relates to compounds of formula I | 02-12-2009 |
20090054451 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity - The present invention is directed to novel piperidine derivatives and to the use of piperidine derivatives of formula I | 02-26-2009 |
20090076026 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 03-19-2009 |
20090099198 | Compounds, Compositions and Methods - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 04-16-2009 |
20090111828 | L-ALANINE DERIVATIVES - The present invention relates to compounds that inhibit of a5 | 04-30-2009 |
20090118298 | Octahydropentalene compounds as chemokine receptor antagonists - The present invention is directed to novel compounds of Formula (I) | 05-07-2009 |
20090124631 | Combination Therapy - The invention relates to the treatment of mammalian diseases manifested by abnormal cell growth and/or abnormal cell proliferation. More particularly, the invention relates to the use of combination therapies to control abnormal cell growth and/or abnormal cell proliferation. In particular, the invention relates to the use of isotype-selective inhibitors of histone deacetylases 1, 2 and/or 3 (HDACs 1-3), as well as isotype-selective inhibitors of HDAC1 and/or HDAC2, to potentiate therapeutic activity of microtubule-stabilization agents. | 05-14-2009 |
20090163511 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same - Disclosed are carboxamide, sulfonamide and amine compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure | 06-25-2009 |
20090170867 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF - The invention relates to compounds of formula IA′ | 07-02-2009 |
20090176797 | PHARMACEUTICAL COMPOSITION FOR TREATING ESOPHAGEAL CANCER - A compound represented by the following formula, a salt thereof or a hydrate of the foregoing is useful as a pharmaceutical composition for treating esophageal cancer treating esophageal cancer. | 07-09-2009 |
20090192168 | Compounds, Compositions and Methods - Certain substituted urea derivatives modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 07-30-2009 |
20090203710 | Novel piperidine derivative - Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder; and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X | 08-13-2009 |
20090221603 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of heterocyclic amides are disclosed of the general formula (1) where Z is N or ═CHNR | 09-03-2009 |
20090247541 | Novel compounds - Compounds of formula (I) | 10-01-2009 |
20090253710 | NMDA Receptor Antagonists for Neuroprotection - Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: | 10-08-2009 |
20090298845 | PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes modulators of MIP-1α of formula (I): | 12-03-2009 |
20090318465 | METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS - The present invention relates to a method for identifying compounds that act as insulin-sensitizers. The method can include screening of test compounds in two assays of insulin sensitivity. This method can identify lead compounds for the treatment of disorders caused by insulin resistance to glucose uptake. This invention also includes methods for treating insulin resistance and related disorders. | 12-24-2009 |
20090318466 | COMPOUNDS USEFUL AS PESTICIDES - Compounds useful to control pests are provided. | 12-24-2009 |
20100010006 | Pharmaceutical Combination for and Method of Anesthetizing and Immobilizing Non-Domesticated Mammals - Non-domesticated mammalian animals are anesthetized and immobilized by injecting an effective amount of an anesthetizing and immobilizing drug comprising pharmaceutically active ingredients of butorphanol tartrate, azaperone tartrate and medetomidine hydrochloride (BAM) into the animal from a dart. The BAM combination is preferably initially formed as lyophilized powder of the pharmaceutically active ingredients, and then reconstituted before injection as an injectable liquid in the environment of the animal. | 01-14-2010 |
20100022554 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA - The present invention provides novel compounds represented by the general formula (I): | 01-28-2010 |
20100029677 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) - Compounds of the formula: | 02-04-2010 |
20100048582 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR - The invention relates to compounds of the formula (I) | 02-25-2010 |
20100048584 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS - Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): | 02-25-2010 |
20100075978 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS - The present invention relates to new sulfonamide derivatives of formula (I) | 03-25-2010 |
20100075979 | PYRIDINYLPIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS - The present invention provides compounds of provides formula I, having affinity and selectivity for the dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use for the therapeutic and/or prophylactic treatment of cognitive disorders. | 03-25-2010 |
20100210664 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR - The invention relates to compounds of the formula R | 08-19-2010 |
20100222362 | N-OXIDES OF N-PHENYL-2-PYRAMIDINE-AMINE DERIVATIVES - The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans. | 09-02-2010 |
20100240675 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - Compounds of formulae: | 09-23-2010 |
20100249144 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS - Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB | 09-30-2010 |
20100267737 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | 10-21-2010 |
20100267738 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF - The present invention relates to inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids. | 10-21-2010 |
20100267739 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE - The use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as pharmaceutical compositions comprising these substances and chemical substances for use in such treatment. | 10-21-2010 |
20100324064 | NOVEL ANALOGS OF CHOLINE FOR NEUROPROTECTION AND COGNITIVE ENHANCEMENT IN NEURODEGENERATIVE DISORDERS - The present invention relates to novel analogs of choline and methods of use or treatment of neurodegenerative disorders and/or conditions such as Parkinson's disease, Huntington disease, Alzheimer's disease and related disorders such as amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease (mad cow disease), dementia with Lewy bodies, schizophrenia, paraneoplastic cerebellar degeneration and neurodegenerative conditions caused by stroke. The present compounds are effective to treat any neurological condition where acetylcholine transmission neurons and their target cells are affected. Compounds according to the present invention are effective to alleviate and/or reverse the effects of a neurodegenerative condition, prevent further deterioration and/or enhance cognition and memory in patients suffering from neurodegenerative disorders, especially Alzheimer's disease. | 12-23-2010 |
20110046151 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR - The present invention is directed to piperazinyl derivatives useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor. | 02-24-2011 |
20110065717 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS - The present invention relates to novel substituted sulfoximine derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. | 03-17-2011 |
20110071159 | 6- (4-CYCLOPROPYLPIPERAZIN-1-YL) -2 ' -METHYL- [3, 4 ' ] -BIPYRIDINE AND ITS USE AS A MEDICAMENT - 6- (4-Cyclopropylpiperazin-1-yl) -2′-methyl- [3, 4′]bipyridinyl and salts and hydrates thereof interact with the histamine H3 receptor are defined. | 03-24-2011 |
20110092513 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES - The present invention relates to novel 5,6-disubstituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the manufacture of a medicament. | 04-21-2011 |
20110124657 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER - The present invention relates to compounds having pharmacological activity towards the 5-HT | 05-26-2011 |
20110144120 | PHENYL-ALKYL PIPERAZINES HAVING TNF-MODULATING ACTIVITY, PREPARATION METHOD, AND THERAPEUTIC USE THEREOF - The present invention relates to phenyl-alkyl piperazines of formula (I): | 06-16-2011 |
20110152285 | PYRROLE ANTIFUNGAL AGENTS - The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides. | 06-23-2011 |
20110172243 | USE OF AZAPERONE FOR REDUCING ANTIBIOTIC USAGE - The present invention relates to a method for the reduction of antibiotic usage in animals through the use of orally administered azaperone. | 07-14-2011 |
20110178096 | OCTAHYDROPENTALENE COMPOUNDS AS CHEMOKINE RECEPTOR ANTAGONISTS - The present invention is directed to novel compounds of Formula (I) | 07-21-2011 |
20110224225 | Inhibitors of protein kinases - Compounds of general Formula (I): | 09-15-2011 |
20110230495 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS - The invention relates to compounds of formula I: | 09-22-2011 |
20110281885 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 11-17-2011 |
20110319421 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR - The invention relates to compounds of the formula R | 12-29-2011 |
20120115879 | METHOD OF TREATMENT FOR MENTAL DISORDERS - The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D | 05-10-2012 |
20120172372 | Ureas and Their Use in the Treatment of Heart Failure - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 07-05-2012 |
20120283267 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GIARDIASIS - Methods of treating exposure to | 11-08-2012 |
20130085146 | LIPID-DRUG FORMULATIONS AND METHODS FOR TARGETED DELIVERY OF LIPID-DRUG COMPLEXES TO LYMPHOID TISSUES - The present application is directed to lipid-drug complexes and related methods for producing stable lipid-drug complexes at or near the neutral pH range and administering pharmaceutical lipid-drug complexes to patients. In certain examples, the lipid-drug complex has a lipid-to-drug molar ratio of approximately 3:1. In certain examples, the lipid-drug complex may have lipid-to-drug molar ratios of less than 3:1 to 10:1 or higher. The present application is also directed to methods of administering a drug to a patient though subcutaneous injection of the lipid-drug complexes into particular tissues to effect higher localized concentrations of the at least one drug. Lipid-anti-HIV-drug complexes can be subcutaneously injected into the lymphoid tissue of a HIV-infected mammalian subject via the lymphatic vessels to deliver high concentrations of stable lipid-anti-HIV-drug complexes, rather than delivery of the anti-HIV drug intravenously via the blood stream which will eventually reach the lymphatic system at lower concentrations. | 04-04-2013 |
20130296335 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 11-07-2013 |
20130317039 | INHIBITION OF DELTA-6 DESATURASE FOR THE TREATMENT OF CARDIOMETABOLIC DISEASE - Systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity are disclosed. Also disclosed is a transgenic mammal which overexpresses a gene encoding delta-6 desaturase and an animal model of a cardiometabolic disorder or disease that includes the transgenic mammal. A method of treating a cardiometabolic disorder or disease is also disclosed. | 11-28-2013 |
20130317040 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING HIV PROTEASE INHIBITORS - The present invention is directed to a method of treating systemic lupus erythematosus (SLE) in a subject comprising administering to the subject an amount of an HIV protease inhibitor effective to treat SLE. The present invention is also directed to a pharmaceutical product comprising an HIV protease inhibitor formulated in a pharmaceutically acceptable carrier, and a package insert providing instructions for the administration of the HIV protease inhibitor for the treatment of SLE. In addition, the present invention is directed to the use of an HIV protease inhibitor for the preparation of a medicament for the treatment of SLE. | 11-28-2013 |
20130324549 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 12-05-2013 |
20130324550 | 1-(2-PHENOXYMETHYLHETEROARYL) PIPERIDINE AND PIPERAZINE COMPOUNDS - The invention relates to compounds of formula I: | 12-05-2013 |
20130338169 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME - The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids. | 12-19-2013 |
20130345233 | INHIBITORS OF PROTEIN KINASES - Compounds of general Formula (I): | 12-26-2013 |
20140011815 | FITNESS ASSAY AND ASSOCIATED METHODS - The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a prodrug, a composition, or an ester thereof, wherein A is a group of formulas (A), (B), (C) or (D); R | 01-09-2014 |
20140038983 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 02-06-2014 |
20140038984 | Compositions and Methods for the Treatment of Metabolic and Related Disorders - The present invention relates to the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. Also provided are methods for the treatment and/or prevention of one or more metabolic disorders, for example, obesity or diabetes, utilizing fatostatin A and/or a derivative and/or analog thereof and/or the A-B-C tripartite compounds. | 02-06-2014 |
20140128407 | FAST DISSOLVING AZAPERONE GRANULATE FORMULATION - The present invention relates to a fast dissolving granulate formulation containing the veterinary drug azaperone and a method for preparing said granulate formulation. | 05-08-2014 |
20140148466 | TRPA1 Receptor Antagonist - A compound of Formula (I), pharmaceutically acceptable salts thereof, enantiomers, or mixtures thereof: pharmaceutical compositions containing said compounds, enantiomers or mixtures, processes for making said compounds, enantiomers or mixtures, the use of said compounds, enantiomers or mixtures, and medicaments containing the same for treatment of pain and other conditions, and methods of treating pain and other conditions with the same. | 05-29-2014 |
20140148467 | Carboxamide Compounds and Methods for Using the Same - Disclosed are carboxamide compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure | 05-29-2014 |
20140194438 | COMPOSITIONS AND METHODS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING - Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery. | 07-10-2014 |
20140200224 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR - The invention formula R | 07-17-2014 |
20140256737 | THERAPEUTIC COMBINATIONS OF NETUPITANT AND PALONOSETRON - Combinations of netupitant and palonosetron, and methods of using such combinations to treat various pain states and irritable bowel syndrome, are provided. | 09-11-2014 |
20140296249 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | 10-02-2014 |
20140309235 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use. | 10-16-2014 |
20140315915 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS - Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds. | 10-23-2014 |
20150290186 | Sedating and Immobilizing Non-Domesticated Mammals - Non-domesticated mammalian animals are sedated and immobilized by injecting an effective amount of pharmaceutically effective combination of nalbuphine hydrochloride and medetomidine hydrochloride into the animal from a dart. Azaperone tartrate may also be included, if desired. | 10-15-2015 |
20150297539 | Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes - The present invention relates to a composition comprising, in combination, metformin or a salt thereof, a pharmaceutically acceptable carrier or excipient and at least one compound of formula (I), the enantiomers, diastereoisomers or pharmaceutically acceptable salts thereof. Formula (I). The present invention also relates to the use of said composition for the treatment of diseases associated with insulin resistance syndrome. | 10-22-2015 |
20150352105 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY - Methods are provided of treating cardiac hypertrophy in a mammalian subject comprising administering to the subject an anti-hypertrophic effective amount of an ion channel TR-PV1 inhibitor. The methods include treatment of a symptom of cardiac hypertrophy in the subject comprises cardiac remodeling, cardiac fibrosis, apoptosis, hypertension, or heart failure | 12-10-2015 |
20160031873 | Carboxamide Derivatives and Use Thereof - The present disclosure provides substituted pyridyl-, pyrimidinyl-, pyrazinyl-, pyridazinyl-, and triazinyl-based carboxamides of Formula I-A: R | 02-04-2016 |
20160060235 | Therapeutic Agent for Type 2 Diabetes - An object of the present invention is to provide a novel therapeutic agent for a patient with type 2 diabetes, a cause of which is the abnormal synthesis of insulin attributed to the abnormal modification of tRNA | 03-03-2016 |
20160090359 | Crystalline Forms of an NK-1 Antagonist - The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders. | 03-31-2016 |
20160115133 | COMPOUNDS, COMPOSITIONS AND METHODS - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 04-28-2016 |
20160168096 | BIARYL DERIVATIVES AS GPR120 AGONISTS | 06-16-2016 |
20170231982 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | 08-17-2017 |